CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,217 enrolled
Drug / intervention
Apixabandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01884350
NCT01884350Phase 4Completed
CompareCT.gov

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)

Bristol-Myers Squibb·interventional·Posted Jun 24, 2013·Updated Aug 19, 2019

In Brief

A Phase 4 clinical trial evaluating Apixaban for Non-valvular Atrial Fibrillation. Completed, enrolled 1,217 participants across 220 sites in 7 countries.

Detailed Summary

The study purpose is to assess the impact of an educational program on patient adherence in patients taking Apixaban for SPAF at 24 weeks

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-valvular Atrial Fibrillation
CountriesBelgium, France, Germany, Italy, Spain, Switzerland, United Kingdom
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 24, 2013
Enrollment StartOct 15, 2013
Primary CompletionJan 20, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.0 years ago

Interventions

Apixabandrug